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Abstract 
Background: The optimal mean arterial pressure (MAP) in cases of septic shock is still a matter of debate in patients 
with prior hypertension. An MAP between 75 and 85 mmHg can improve glomerular filtration rate (GFR) but its effect 
on tubular function is unknown. We assessed the effects of high MAP level on glomerular and tubular renal function 
in two intensive care units of a teaching hospital. Inclusion criteria were patients with a history of chronic hyperten‑
sion and developing AKI in the first 24 h of septic shock. Data were collected during two 6 h periods of MAP regimen 
administered consecutively after haemodynamic stabilisation in an order depending on the patient’s admission unit: 
a high‑target period (80–85 mmHg) and a low‑target period (65–70 mmHg). The primary endpoint was the creatinine 
clearance (CrCl) calculated from urine and serum samples at the end of each MAP period by the UV/P formula.
Results: 26 patients were included. Higher urine output (+0.2 (95%:0, 0.4) mL/kg/h; P = 0.04), urine sodium (+6 (95% 
CI 0.2, 13) mmol/L; P = 0.04) and lower serum creatinine (− 10 (95% CI − 17, − 3) µmol/L; P = 0.03) were observed 
during the high‑MAP period as compared to the low‑MAP period, resulting in a higher CrCl (+25 (95% CI 11, 39) mL/
mn; P = 0.002). The urine creatinine, urine–plasma creatinine ratio, urine osmolality, fractional excretion of sodium and 
urea showed no significant variation. The KDIGO stage at inclusion only interacted with serum creatinine variation and 
low level of sodium excretion at inclusion did not interact with these results.
Conclusions: In the early stage of sepsis‑associated AKI, a high‑MAP target in patients with a history of hypertension 
was associated with a higher CrCl, but did not affect the kidneys’ ability to concentrate urine, which may reflect no 
effect on tubular function.
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Background
Acute kidney injury (AKI) is a common clinical problem 
affecting approximately 50% of intensive care patients 
[1]. Sepsis is its main cause in this setting [2]. Tradi-
tional hemodynamic management of sepsis-associated 
AKI focuses on the prevention of hypoperfusion by 
optimizing blood pressure to maintain renal perfusion 
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pressure and thus glomerular filtration rate (GFR), pri-
marily through fluid resuscitation and administration of 
vasopressor drugs. However, optimizing blood pressure 
to limit kidney damage is a daily challenge for intensiv-
ists, especially since the optimal mean arterial pres-
sure (MAP) target remains a subject of debate [3–7]. In 
patients with septic shock, the Surviving Sepsis Cam-
paign guidelines recommend an initial target MAP of 
65 mmHg. It is also highlighted that when a better under-
standing of any patient’s condition is obtained, the MAP 
target should be individualized to the pertaining circum-
stances as it may be too low for certain patients [3]. In 
particular, the threshold for renal autoregulation may be 
higher in patients with atherosclerosis and/or previous 
hypertension than in young patients without cardiovas-
cular comorbidity. European expert recommendations 
suggest higher MAP target in septic shock patients with 
history of hypertension and in patients that show clinical 
improvement with higher blood pressure [4].
On the other hand, there may be a risk of excessive 
vasoconstriction at higher MAP target requiring higher 
norepinephrine infusion rates, particularly in cases of 
sepsis-associated AKI where the pathophysiological 
mechanisms are complex [5]. Sepsis-associated AKI is 
characterized at an early stage by increased renal blood 
flow and decreased renal vascular conductance, result-
ing in redistribution of intrarenal blood flow and reduced 
medullar perfusion and oxygenation [1, 6]. Restoration 
of blood pressure by norepinephrine infusion improves 
renal perfusion pressure but may further reduce renal 
medullary perfusion at high concentrations [6]. A higher 
MAP target could then improve blood pressure on the 
glomeruli, located in the renal cortex, without ben-
efiting renal tubular function dependent on medullary 
perfusion.
The objective of this study was to analyse the effects 
of a high-MAP target on renal glomerular and tubular 




During a 12-month study period (August 2016–July 
2017), we included patients with a history of chronic 
hypertension and developing AKI at any KDIGO stage in 
the first 24 h of septic shock in two intensive care units 
(ICU) of Bordeaux University Hospital (one medico-sur-
gical ICU including pulmonary or abdominal surgery and 
one medical ICU). Exclusion criteria were pregnancy, 
age ≤ 18  years, obstructive renal disease, AKI from an 
obstructive or suspected cause other than sepsis (e.g., 
toxic), severe chronic kidney disease defined based on 
a known eGFR < 30  mL/min/1.73   m2, renal replacement 
therapy (RRT) or anuria at the time of inclusion, and a 
presumed life expectancy < 24 h. Approval for this study 
was obtained from our institutional review board (Trial 
registration: DC 2016/81, Comité de Protection des Per-
sonnes Sud-Ouest et Outre Mer III, France; http:// www. 
cpp- soom3.u- borde aux2. fr/; Registered June 2016). All 
patients or their family agreed to participate in the study.
Definitions
Patients were defined as having chronic hypertension 
when they were known to be hypertensive in their past 
medical history with at least one antihypertensive treat-
ment in their usual medication regimen. Septic shock 
was defined according to the sepsis-3 definition [7]. AKI 
was defined according to the Kidney Disease Improving 
Global Outcomes (KDIGO) classification on the criteria 
of urine output (UO) and serum creatinine (sCr) [8]. The 
baseline sCr was determined by calling the referring doc-
tor or by analysing the patient’s medical records within 
the prior 3 months.
Procedures
The attending physician treated patients in accord-
ance with the recommendations of the Surviving Sepsis 
Campaign after admission to ICU [3]. Initial manage-
ment included fluid challenges to achieve a minimum of 
30  mL/kg crystalloids and avoid excessive vasoconstric-
tion in hypovolemic patients. Fluid administration was 
continued if there was haemodynamic improvement 
based on dynamic criteria (e.g., change in stroke vol-
ume). Haemodynamic was continuously monitored for 
all patients by an arterial line and repeated echocardi-
ography. The administration of norepinephrine was per-
formed to reach an initial MAP target of 65 mmHg.
After haemodynamic stabilisation defined as a 3  h 
stable or decreased dose of norepinephrine without a 
need for fluid loading, the MAP target was challenged 
in accordance with the recommendations [4, 9]. Patients 
were studied during two consecutive 6-h periods of MAP 
regimen administered consecutively in an order that 
depended on the ICU to which the patient was admit-
ted: a group A with a high target period with MAP of 
80–85 mmHg followed by a low-target period with MAP 
of 65–70  mmHg and a group B with a low MAP target 
period followed by a high MAP target period (Fig.  1). 
The order of assignment of the MAP regimens depended 
on the two participating ICU and the treatment was 
not blinded to the investigators or participants. Norepi-
nephrine was titrated by the attending physician and the 
ICU nurses to achieve the MAP target according to unit 
protocols.
During the high-MAP target period, a reduction 
in vasopressor doses to maintain an MAP of 65 to 
Page 3 of 10Dewitte et al. Ann. Intensive Care          (2021) 11:139  
70  mmHg was recommended if any of the prespeci-
fied serious adverse events that were potentially related 
to an increased rate of vasopressor infusion occurred. 
These events clinically relevant were bleeding, rhythm 
disorders, suspicion of myocardial infarction, mesenteric 
ischemia or distal-limb ischemia.
Data collection
All data, including hourly UO, were collected over a 
period of 6  h for each MAP target. Patient monitoring 
software (Metavision; iMDSoft, Wakefield, MA, USA) 
was used to continuously record all variables with a time 
interval of 1 min. The data were automatically averaged 
for each point analyzed.
Endpoints
The primary endpoint of this study was the GFR esti-
mated by calculating creatinine clearance (CrCl) with 
the UV/P formula [9]. CrCl was determined from a urine 
sample obtained from the collection of the last hour of 
each MAP period. Urine and blood samples were col-
lected simultaneously at inclusion and at each change in 
MAP target (Fig. 1). The other secondary endpoints were 
the sCr, urine creatinine (UCr), UO, urine sodium (UNa), 
serum osmolality, urine osmolality, proteinuria, urine-to-
plasma creatinine ratio, fractional excretion of sodium 
(FeNa) and fractional excretion of urea (FeU) variations 
from low to high-MAP period. The occurrence of adverse 
events was also analysed.
Statistical analyses
We estimated that at least 20 patients with AKI would 
be needed in this study to have 80% power to detect a 
20% difference in CrCl between the two periods at a 
two-sided alpha level of 0.05. This calculation was based 
on the assumption that the standard deviation of the dif-
ference between the two CrCl values for the same patient 
would be 30%. Quantitative parameters are reported as 
their mean (standard deviation) or median [interquar-
tile range] as appropriate and qualitative parameters are 
expressed as numbers (percentages). Baseline character-
istics were compared using the χ2 test or Fisher’s exact 
test as appropriate. Continuous variables were com-
pared using the Mann–Whitney U test. We performed 
a multivariate repeated measures analysis of variance 
(MANOVA) to compare the primary and secondary 
endpoints between the inclusion and the low MAP regi-
men and between the low and the high MAP regimen, 
including the order of assignment of MAP regimes and 
the KDIGO stage at inclusion as factors. Analysis of the 
interaction of pre-inclusion ACE inhibitor treatment, 
time from initiation of norepinephrine to inclusion, 
level of sodium excretion at inclusion and norepineph-
rine dose to achieve a high-MAP target on the variables 
studied was also assessed using multivariate repeated 
measures analysis of variance (MANOVA). All tests were 
two-sided with an alpha level of 0.05. Statistical analy-
ses were performed using SAS version 9.3 (SAS Insti-
tute, Cary, NC, USA) and GraphPad Prism version 6.00 
(GraphPad Software, La Jolla, CA, USA).
Results
Study population
Twenty-six patients were included in the study. The flow 
chart and the characteristics of the patients are shown in 
Fig. 2 and Table 1. All antihypertensive treatments were 
stopped at the onset of septic shock. No patients received 
diuretic therapy after admission to the ICU. All patients 
Fig. 1 Study design
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were mechanically ventilated. The median time from 
initiation of norepinephrine to inclusion was 18 [12–24] 
h. The fluid balance was positive before inclusion with a 
median of 54 [38–93] mL/kg since ICU admission. No 
patients died during the study (Table 2). Six patients were 
treated with RRT after the study period with a median 
time from admission to initiation of RRT of 93 [16–144] 
h.
Vasopressor use and fluid balance between low‑ 
and high‑MAP periods
All patients were receiving norepinephrine during the 
study period. MAP was significantly different between 
the low-MAP and high-MAP periods (72 [68–78] vs. 85 
[83–89] mmHg in group A and 68 [66–72] vs. 85 [82–89] 
in group B; P < 0.0001) (Fig. 3). To obtain a higher MAP 
target, patients received higher doses of norepineph-
rine (0.3 [0.1–0.5] vs. 0.5 [0.3–0.6] µg/kg/min in group 
A and 0.3 [0.2–0.6] vs. 0.5 [0.4–0.6] µg/kg/min in group 
B; P < 0.0001). No patients received fluid loading during 
the protocol period. There was no difference in fluid bal-
ance during the low- and high-MAP target periods (4 
[− 1 to 6] vs. 6 [4–11] mL/kg in group A and 9 [4–11] 
vs. 8 [4–16] mL/kg in group B; P = 0.6). There was no sig-
nificant interaction of the group or the KDIGO stage at 
inclusion on these results.
Endpoints
The intra-individual variations of the studied parameters 
from low- to high-MAP target and their values at inclu-
sion are presented in Table 3. No parameters differ signif-
icantly between their value at inclusion and the low-MAP 
target period (Additional file 1: Figure S1). The CrCl was 
higher during the high-MAP period compared to the 
low-MAP period with an intra-individual percentage var-
iation of 88 [7–227] % (P = 0.002) (Fig. 4). The high-MAP 
period was associated with a significant intra-individual 
increase of UO (11 [− 7 to 76] %; P = 0.04) and UNa (11 
[− 8 to 46] %; P = 0.04) and a decrease of sCr (− 5 [− 12 
to 1] %; P = 0.03) compared to the low-MAP period. 
There was no significant variation in uCr, urine osmolal-
ity, serum osmolality, FeNa and FeU between the low and 
the high-MAP period.
Fig. 2 Flow chart of the study
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Urine concentration ability according to the natriu-
resis at inclusion are shown in Fig.  5. Patients with 
UNa < 30  mmol/L at inclusion had no significant dif-
ference in intra-individual variations of UNa, UOsm, 
urine-to-plasma creatinine ratio, FeNA and FeU from 
low to high-MAP target period compared to those with 
UNa > 30 mmol/L at inclusion.
Table 1 Baseline characteristics of patients (n = 26)
Data are expressed as the median [interquartile range] or number (%)
a Calculated using the CKD-EPI formula
b Calculated using the UV/P formula
ARB: angiotensin II receptor blocker; sCr: serum creatinine; SOFA: Sepsis-related Organ Failure Assessment; SAPS II: simplified acute physiology score II; eGFR: 
estimated glomerular filtration rate; MAP: mean arterial pressure; ICU: intensive care unit
Characteristics All patients
(n = 26)
Group A: from high to low 
MAP target
(n = 14)





Age (year) 69 [61–75] 68 [61–75] 69 [60–75] 0.7
Male 21 (80) 11 (79) 10 (83) 0.8
Weight (kg) 80 [65–94] 80 [65–95] 82 [59–100] 0.8
Body Mass Index 27 [24–32] 28 [24–31] 26 [22–32] 0.8
Reason for admission 0.05
 Medical 10 (38) 3 (21) 7 (58)
 Surgical 16 (62) 11 (79) 5 (42)
Antihypertensive treatment 0.4
 Calcic inhibitor 13 (50) 8 (57) 5 (42)
 Angiotensin converting enzyme inhibitor 10 (39) 5 (36) 9 (75)
 Beta‑blockers 11 (42) 5 (36) 6 (50)
 Diuretic 2 (8) 1 (7) 1 (8)
Comorbidities 0.8
 Coronaropathy 7 (27) 4 (29) 3 (25)
 Valvular disease 3 (12) 1 (7) 2 (17)
 Rhythmic disease 8 (31) 5 (36) 3 (25)
 Heart failure 4 (15) 3 (21) 1 (8)
 Peripheral arterial disease 1 (4) 1 (7) 0 (0)
 Ischemic stroke 1 (4) 1 (7) 0 (0)
 Chronic kidney failure 4 (15) 3 (21) 1 (8)
 Respiratory disease 8 (31) 4 (29) 4 (33)
 Diabetes mellitus 10 (39) 6 (43) 4 (33)
 Neoplastic disease 10 (39) 7 (50) 3 (25)
 Smoking 7 (27) 4 (29) 3 (25)
Prior kidney function
 Baseline sCr (µmol/L) 71 [53–90] 68 [41–90] 73 [60–90] 0.6
 Baseline  eGFRa (mL/min/1.73  m2) 92 [75–104] 92 [74–114] 89 [76–97] 0.6
Characteristics at inclusion
 SOFA score 9 [7–13] 9 [6–10] 9 [7–14] 0.5
 SAPS II score 52 [36–62] 48 [34–53] 61 [41–73] 0.04
 Time from initiation of norepinephrine to inclusion 
(hours)
18 [12–24] 18 [16–24] 16 [10–23] 0.3
Baseline KDIGO stage 0.6
 1 9 (35) 4 (29) 5 (42)
 2 13 (50) 7 (50) 6 (50)
 3 4 (15) 3 (21) 1 (8)
sCr (µmol/L) 124 [75–192] 143 [116–206] 105 [69–155] 0.1
MAP (mmHg) 71 [65–72] 71 [69–73] 67 [65–73 0.2
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Interaction analysis
The order of assignment of MAP regimens did not 
significantly affect the effects of MAP on the varia-
bles analysed (Table 2 and Additional file 1: Table S1). 
Analysis of the interaction of the KDIGO stage at 
inclusion only showed a significant interaction on the 
variation of sCr between the low and high-MAP tar-
get period (P value for interaction = 0.04) (Additional 
file  1: Table  S2). Treatment with ACE inhibitors prior 
to inclusion, time from initiation of norepinephrine to 
inclusion > 18 h, NaU at inclusion < 30 mmol/L and nor-
epinephrine dose required to achieve a high MAP tar-
get > 0.5 µg/kg/min also did not interact with the effects 
of the high vs. low-MAP period on CrCl or any of the 
secondary endpoints.
Adverse events
Higher level of MAP target was not associated with more 
adverse events: seven patients (27%) presented with 
rhythm disorders (atrial fibrillation) regardless of MAP 
level. None of the patients suffered from acute coro-
nary events, bleeding, mesenteric ischemia or cutaneous 
necrosis between the low- and high-MAP target period 
(troponin level [0.005–0.145] ng/mL vs. 0.03 [0–0.11] ng/
mL, P = 0.4). Lactate and pH remained similar between 
the low- and high-MAP target period (1.4 [1.1–1.2] 
mmol/L vs. 1.4 [1–1.9] mmol/L; P = 0.7 and 7.40 [7.32–
7.44] vs. 7.39 [7.33–7.44], respectively; P = 0.13).
Discussion
The main finding of this study is that a high-MAP target 
of 80–85 mmHg compared to MAP of 65–70 mmHg in 
septic patients with AKI and prior hypertension is associ-
ated with increased UO, UNa and decreased sCr, result-
ing in increased glomerular function as assessed by the 
UV/P formula. Conversely, a high-MAP regimen does 
not affect the kidneys’ ability to concentrate urine, with 
no variation in urinary osmolality, urine-to-plasma cre-
atinine ratio and fractional excretion of sodium or urea, 
which may reflect no effect on tubular function.
The evaluation of renal function is complex in criti-
cally ill patients. Serum creatinine is traditionally used, 
because it is freely filtered into the glomerulus, with a 
small proportion being secreted along the tubule. The 
recommended formula for estimating GFR is UV/P, 
because it has the potential advantage that it can be 
used in the absence of a stable state [10]. However, its 
main limitations are that many factors influence sCr, in 
particular the patient’s volume of distribution [11] and 
the proportion of tubular creatinine secretion, which 
remains unpredictable and depends on the relative 
increase in sCr to the patient’s baseline creatinine [10]. 
However, the kidney has many other functions that are 
Table 2 Patient outcomes
Data are expressed as the median [interquartile range] or number (%)
Outcomes All patients
(n = 26)
Group A: from high to low 
MAP target
(n = 14)




Renal replacement therapy 6 (24) 4 (31) 2 (17) 0.4
Time from diagnosis of septic shock to initiation of 
renal replacement therapy (hours)
93 [16–144] 93 [27–136] 81 [18–144] 0.8
ICU, length of stay (days) 15 [13–33] 22 [15–57] 13 [10–25] 0.07
Hospital, length of stay (days) 30 [25–48] 33 [21–72] 29 [23–44] 0.7
ICU Mortality 10 (38) 4 (29) 6 (50) 0.5
Hospital Mortality 11 (42) 5 (36) 6 (50) 0.5
























Group A: from high to low MAP target
Group B: from low to high MAP target
P<0.0001*
Fig. 3 MAP evolution during the high‑MAP target period and the 
low‑MAP target period. *P values for the within‑subject comparison 
of MAP using a multivariate repeated‑measures analysis of variance 
(MANOVA)
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difficult to assess in AKI, including tubular transport. The 
ability of loop diuretics that are active on the renal tubule 
to induce natriuresis has, for example, been used to pre-
dict the development and severity of AKI and its progno-
sis [12]. To our knowledge, no studies have estimated the 
impact of higher pressure regimen on tubular function in 
sepsis-associated AKI.
The effects of MAP level on AKI have been investi-
gated in numerous studies, showing an improvement in 
UO with a MAP target between 65 and 75 mmHg [13]. 
Table 3 Blood and urine parameters according to mean arterial pressure regimen (n = 26)
Data are expressed as the mean (SD) and mean individual difference (IC95%) from low- to high-MAP target period
P values for the within-subject comparisons between the low and the high-MAP target period a multivariate repeated-measures analysis of variance (MANOVA) 
including the order of assignment of MAP regimes and the KDIGO stage at inclusion as factors
a Calculated using the UV/P formula
MAP: mean arterial pressure; KeGFR: kinetic estimated glomerular filtration rate






P values for Group‑
MAP interaction
P values for 
effect of MAP
Primary endpoint
 Creatinine clearance (mL/mn)a 34 (24) 32 (31) 58 (41) 25 (11, 39) 0.1 0.002
Secondary endpoints
 Serum creatinine (µmol/L) 142 (80) 150 (85) 141 (80) − 10 (− 17, − 3) 0.5 0.03
 Urine creatinine (mmol/L) 7.3 (4.6) 7.7 (6.1) 6.5 (4.1) − 1.1 (− 2.2, 0.05) 0.2 0.06
 Urine output (mL/kg/h) 0.7 (0.5) 0.8 (0.6) 1 (0.7) 0.2 (0, 0.4) 0.3 0.04
 Urine sodium (mmol/L) 44 (30) 40 (26) 59 (26) 6 (0.2, 13) 0.8 0.04
 Serum osmolality (mOsm/kg) 308 (18) 307 (18) 306 (15) − 0.1 (− 2.1, 1.9) 0.2 0.8
 Urine osmolality (mOsm/kg) 436 (141) 456 (179) 433 (126) 3 (− 18, 25) 0.1 0.9
 Proteinuria (g/L) 1.2 (0.8) 1.1 (0.6) 1.2 (0.7) 0.07 (− 0.1, 0.3) 0.9 0.4
 Urine–plasma creatinine ratio 75 (72) 78 (86) 70 (71) − 7 (− 21, 7) 0.8 0.1
 Fractional excretion of sodium 0.9 (1.1) 1.1 (1.7) 1.2 (1.4) 0.02 (− 0.2, 0.3) 0.8 0.8
 Fractional excretion of urea 31 (17) 32 (13) 36 (17) 2.2 (− 1.7, 6.1) 0.2 0.3
-100 0 100 200 300
Fractional Excretion of Urea



























Fig. 4 Primary and secondary endpoints. Intra‑individual variations in blood and urine parameters from low to high‑MAP target period, expressed 
as a percentage. GFR was estimated by the UV/P (Creatinine Clearance). P values for the within‑subject comparison of MAP using a multivariate 
repeated‑measures analysis of variance (MANOVA)
Page 8 of 10Dewitte et al. Ann. Intensive Care          (2021) 11:139 
In the SEPSISPAM trial, 778 patients with septic shock 
were randomly treated with a low (65–70  mmHg) vs. 
high (80–85 mmHg) MAP target [14]. The authors dem-
onstrated less renal failure, as defined by the doubling of 
plasma creatinine (38.8% vs. 52.0%, respectively, P = 0.02) 
in patients with previous hypertension treated with a 
higher MAP target and a decrease number of patients 
requiring RRT. Conversely, the 65-trial comparing per-
missive hypotension to usual care in patients 65 years of 
age or older receiving vasopressors for vasodilatory hypo-
tension did not demonstrate an increase in the use of 
RRT in patients with chronic hypertension randomized 
to a lower MAP target group [15]. Legrand et  al. also 
did not observe an association between most systemic 
hemodynamic parameters, including MAP and car-
diac output, and sepsis-associated AKI [16]. Our results 
confirm that in patients with sepsis-associated AKI and 
chronic hypertension, a higher MAP target is associated 
with a significant increase in UO and a decrease in sCr, 
resulting in better CrCl. The observed increase in CrCl 
may not be considered as the only result of the increase 
in UO (e.g., single doses of diuretics have no significant 
effect on CrCl [17]), but could rather be the consequence 
of a residual level of glomerular filtration function when 
capillary pressure increases during a high-MAP regi-
men [18, 19]. The stage of AKI interacted with variations 
in sCr in our study, possibly due to higher sCr values in 
patients with the most severe renal injury. More origi-
nally, we showed no variation in the ability to concentrate 
urine at a high-MAP regimen. Increased renal perfu-
sion could, for instance, have curbed sodium reabsorp-
tion, but patients with low sodium excretion at inclusion 
showed no significant change in their ability to concen-
trate urine at high-MAP regimen compared to those 
with higher sodium excretion at inclusion. Furthermore, 
proximal tubular creatinine secretion accounts normally 
for 10–20% of the total creatinine clearance but increases 
to 50% in chronic kidney disease (CKD) when GFR falls 
[20]. The high-MAP regimen in our study did not result 
in a significant increase in uCr, which may also reflect no 
effect on tubular secretion of creatinine.
This study has several limitations. First, this study 
should be considered exploratory and observational as 


































































































































































Fig. 5 Urine concentration ability according to the natriuresis at inclusion. Intra‑individual variations of urine sodium (UNa), urine osmolality 
(UOsm), urine‑to‑plasma creatinine ratio (U/P creat ratio), fractional excretion of sodium (FeNA) and fractional excretion of urea (FeU) from low to 
high‑MAP target period according to UNa at inclusion, expressed as a percentage
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and not at the level of the grouping unit without ran-
domisation. A carry-over effect remains, therefore, pos-
sible in this rapidly evolving disease without being able to 
assume that the patients had returned to their initial state 
before the application of the next MAP regimen. How-
ever, changes in creatinine clearance are described as 
rapid in AKI, with a period of approximately 7 h to reach 
a 100% increase when the baseline SCr is 88 µmol/L at a 
constant rate of creatinine production of 60 mg/h and a 
complete cessation of CrCl [21]. A washout period was 
also possible on the urine sample, since it was collected 
on the last hour collection. The time to assess a change in 
renal tubular function is not known for this clinical set-
ting either, but response to renal tubular function tests is 
often observed within hours in nephrology studies [22]. 
Second, patients were included after the initial resuscita-
tion of septic shock, i.e., after the crucial period for the 
onset and severity of AKI. The inclusions may then have 
been too delayed for the MAP-targeted norepinephrine 
regimen to have a significant impact on tubular func-
tion. Patient evolution prior to admission to the ICU may 
also have influenced our results and the time period for a 
potential impact of higher MAP regimen on renal func-
tion and its lasting effect is unknown. The haemodynamic 
stabilisation period defined by a stable or decreased dose 
of norepinephrine for 3-h fluid loading could also be 
debated. This delay was chosen to allow sufficient time 
to reach an optimised volume status before changing 
doses of norepinephrine, but without excessively delay-
ing the possible effect of the change in pressure regimen 
on renal function. Estimation of GFR by calculation of a 
CrCl from a urine sample may be another limiting factor 
as it may not be representative of urine production over 
a longer period of time [9]. However, our analysis at an 
intra-individual level in combination with an MAP regi-
men administered consecutively in two different orders 
may avoid other biases related to the normal evolution 
of sepsis-associated AKI, given the great diversity of 
septic patients, including the patient’s creatinine genera-
tion rate, the volume of distribution of creatinine, and 
dynamic changes over time as well as “renal reserve” of 
patients.
The pathophysiological mechanisms underlying sepsis-
associated AKI are still a matter of debate, but it has been 
demonstrated that AKI occurs during hyperdynamic sep-
sis with increased total renal blood flow [5, 23]. Several 
mechanisms have been proposed to play a role, including 
tissue hypoxia, changes in microcirculation, venous con-
gestion and mechanisms independent of haemodynamic 
impairment, such as inflammation and oxidative stress. 
Beyond the filtration function of the kidney, tubular 
transport is a determining factor in its oxygen consump-
tion and evidence is now accumulating that places the 
tubular system at the center of AKI pathophysiology and 
recovery in established sepsis [24]. In addition, recent 
findings suggest that treatment with norepinephrine 
decreased medullary tissue oxygen tension by half and 
decreased medullary perfusion, region in which the renal 
tubules are inserted [6]. The increase in GFR during nor-
epinephrine infusion may also increase sodium delivery 
to tubular elements within the medulla, and thus utiliza-
tion of oxygen for sodium reabsorption, which could con-
tribute to the observed medullary hypoxia [25]. Whether 
the risk of medullary hypoxia associated with high doses 
of norepinephrine combined to pressure induced glo-
merular injuries, which is the predominant pathway for 
nephron loss in CKD [26], have an impact on renal injury 
and its long-term prognosis is unknown. However, it is 
now well established that AKI survivors are at high risk 
of developing CKD, even if their AKI was not severe and 
their kidney function has recovered on discharge from 
the ICU [27]. The impact of a high-MAP target on renal 
tubular function and on the longer term prognosis of 
sepsis-associated AKI in patients with prior hypertension 
should be further investigated in larger randomised trials.
Conclusion
In the early stage of sepsis-associated AKI, a higher 
MAP target of 80–85  mmHg as compared to a stand-
ard MAP target of 65–70 mmHg in patients with prior 
hypertension was associated with a significant greater 
glomerular function evaluated by the UV/P formula, 
but did not affect the kidneys’ ability to concentrate 
urine, which may indicate no effect on tubular function.
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